Dyne Therapeutics, Inc. (DYN) Income Statement
DYN 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsDYN revenue and net income
DYN profit margins
DYN growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
DYN quarterly EPS vs estimates
Dyne Therapeutics beat the analyst EPS estimate in 4 of the last 8 quarters. Next report: November 4, 2026 (estimate $-0.88).
DYN income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $506.0M | $1.37B |
| Cost of revenue | $2.0M | $2.2M | $2.5M | $3.3M | $1.1M | $700,000 | $271,000 | $24,000 | $2.93B | $2.28B |
| Gross profit | −$2.0M | −$2.2M | −$2.5M | −$3.3M | −$1.1M | −$700,000 | −$271,000 | −$24,000 | −$2.43B | −$915.0M |
| Research & development | $398.3M | $281.4M | $210.8M | $142.8M | $121.3M | $45.2M | $11.0M | $4.3M | — | — |
| Sales, general & admin | $69.9M | $62.5M | $31.4M | $28.2M | $28.7M | $13.4M | $2.8M | $517,000 | $189.0M | $161.0M |
| Total operating expenses | $466.1M | $341.6M | $239.7M | $171.0M | $150.0M | $58.6M | $13.8M | $4.8M | $189.0M | $161.0M |
| Operating income | −$468.2M | −$343.9M | −$242.2M | −$171.0M | −$150.0M | −$58.6M | −$13.8M | −$4.8M | −$412.0M | −$640.0M |
| Interest income | $29.9M | $26.9M | $7.2M | $2.9M | $742,000 | $56,000 | $290,000 | $5,000 | — | — |
| Interest expense | $6.2M | $0 | $0 | $2.9M | $742,000 | $396,000 | $290,000 | $5,000 | $616.0M | $625.0M |
| Income before taxes | −$446.2M | −$317.4M | −$235.9M | −$168.1M | −$149.3M | −$59.4M | −$14.9M | −$4.8M | −$538.0M | −$1.29B |
| Income taxes | — | — | −$235.9M | −$2.9M | −$8,000 | −$700,000 | −$1.3M | −$11,000 | −$610.0M | −$45.0M |
| Net income | −$446.2M | −$317.4M | −$235.9M | −$165.2M | −$149.3M | −$58.7M | −$13.5M | −$4.8M | $76.0M | −$1.24B |
| EBITDA | −$438.0M | −$315.7M | −$234.3M | −$169.3M | −$148.2M | −$57.9M | −$14.6M | −$4.8M | $949.0M | $106.0M |
| EPS (diluted) | −$3.51 | −$3.35 | −$3.94 | −$3.24 | −$2.91 | −$1.34 | −$1.06 | — | −$2.40 | −$3.06 |
| Gross margin | — | — | — | — | — | — | — | — | −479.4% | −67.0% |
| Operating margin | — | — | — | — | — | — | — | — | −81.4% | −46.9% |
| Net margin | — | — | — | — | — | — | — | — | 15.0% | −90.8% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $1.6M | $0 | $0 | $0 | $3.8M | $0 |
| Cost of revenue | — | $550,000 | $521,000 | — | $500,000 | $502,000 | $786,000 | $400,000 | $400,000 | $386,000 | $567,000 | $597,000 |
| Gross profit | — | −$550,000 | −$521,000 | — | −$500,000 | −$502,000 | $786,000 | −$400,000 | −$400,000 | −$386,000 | $3.2M | −$597,000 |
| Research & development | $152.2M | $100.9M | $95.4M | $97.2M | $99.2M | $106.4M | $81.8M | $92.8M | $62.3M | $44.5M | $58.8M | $55.3M |
| Sales, general & admin | $29.5M | $24.4M | $20.7M | $16.7M | $16.6M | $15.9M | $15.3M | $12.9M | $10.1M | $24.6M | $9.4M | $7.0M |
| Total operating expenses | $181.7M | $125.3M | $115.6M | $113.9M | $115.8M | $122.4M | $97.1M | $105.7M | $72.0M | $69.2M | $67.7M | $62.3M |
| Operating income | −$181.7M | −$125.3M | −$116.1M | −$113.9M | −$115.8M | −$122.4M | −$97.1M | −$105.7M | −$72.0M | −$69.2M | −$67.7M | −$62.3M |
| Interest income | $7.8M | $8.8M | $7.7M | $8.5M | $6.6M | $7.1M | $7.6M | $9.3M | $7.1M | $3.0M | $1.8M | $2.2M |
| Interest expense | $4.6M | $4.2M | $3.2M | $2.9M | $94,000 | $0 | — | — | $0 | — | $1.7M | — |
| Income before taxes | −$178.6M | −$120.9M | −$112.0M | −$108.0M | −$110.9M | −$115.4M | −$89.5M | −$97.1M | −$65.1M | −$65.6M | −$66.6M | −$60.2M |
| Income taxes | — | — | — | — | — | — | — | — | −$1 | −$3.0M | $4.3M | −$431,000 |
| Net income | −$178.6M | −$120.9M | −$112.0M | −$108.0M | −$110.9M | −$115.4M | −$89.5M | −$97.1M | −$65.1M | −$65.6M | −$66.6M | −$60.2M |
| EBITDA | −$173.4M | −$116.1M | −$101.2M | −$104.6M | −$110.3M | −$114.9M | −$89.1M | −$96.7M | −$64.7M | −$65.3M | −$66.2M | −$59.8M |
| EPS (diluted) | −$1.08 | −$0.73 | −$0.73 | −$0.76 | −$0.97 | −$1.05 | −$0.88 | −$0.96 | −$0.70 | −$0.81 | −$1.09 | −$0.99 |
| Gross margin | — | — | — | — | — | — | 50.0% | — | — | — | 85.0% | — |
| Operating margin | — | — | — | — | — | — | −6,177.4% | — | — | — | −1,786.9% | — |
| Net margin | — | — | — | — | — | — | −5,696.1% | — | — | — | −1,759.2% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in DYN's financial statements (latest annual report filed March 2, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
DYN financial results
Dyne Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $446.2 million. Diluted earnings per share came to −$3.51.
See the DYN stock overview for the latest quote and news, or the DYN chart for price history and technical indicators.
DYN income statement FAQ
Does Dyne Therapeutics have revenue?
Dyne Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Dyne Therapeutics profitable?
No. Dyne Therapeutics reported a net loss of $446.2 million in fiscal 2025.
How much does Dyne Therapeutics spend on research and development?
Dyne Therapeutics spent $398.3 million on research and development in fiscal 2025.
What are Dyne Therapeutics's earnings per share?
Dyne Therapeutics earned $-3.51 per diluted share in fiscal 2025, compared with $-3.35 a year earlier.
When will Dyne Therapeutics report its next earnings?
Dyne Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 4, 2026.
When does Dyne Therapeutics's fiscal year end?
Dyne Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 2, 2026.